Company Tharimmune, Inc.

Equities

THAR

US4327052001

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-21 pm EDT			5-day change	1st Jan Change
0.3905 ^USD	+3.86%		+7.10%	-23.28%

May. 09	Tharimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 23	Tharimmune, Inc. Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates	CI

Tharimmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of therapeutic candidate for inflammatory and immunologic conditions. It has a transmucosal film product, TH104 in Phase I clinical development, two bispecific candidates and a Picobody candidate in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active compound nalmefene onto a thin film which adheres inside of the mouth on the cheek and biodegrades. TH104 is an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. It is also developing an early-stage pipeline of novel therapeutic candidates targeting validated high value immune-oncology (IO) targets including human epidermal growth factor (EGF) receptor 2 (HER2), human EGF receptor 3 (HER3) and programmed cell death protein (PD-1). The Company is developing antibodies, including bispecific antibodies, antibody drug conjugates (ADCs) and others.

Number of employees: 3

Managers	Title	Age	Since
Randy Milby CEO	Chief Executive Officer	70	16-12-31
Thomas Hess DFI	Director of Finance/CFO	60	21-05-31
Ron Weitzman CTO	Chief Tech/Sci/R&D Officer	-	-
Sireesh Appajosyula COO	Chief Operating Officer	48	21-06-30
Robert Niecestro LAW	General Counsel	67	-

Members of the board	Title	Age	Since
Randy Milby CEO	Chief Executive Officer	70	16-12-31
Leonard Mazur BRD	Director/Board Member	79	21-06-30
Kelly Anderson BRD	Director/Board Member	56	23-05-08
Lynne Bui BRD	Director/Board Member	53	21-06-30
Sireesh Appajosyula COO	Chief Operating Officer	48	21-06-30

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	11,793,309	11,577,653 ( 98.17 %)	3,633 ( 0.0308 %)	98.17 %

Name	Equities	%	Valuation
Randy Milby 1.333 %	156,517	1.333 %	56 503 $
Sireesh Appajosyula 0.4307 %	50,557	0.4307 %	18 251 $
XTX Topco Ltd. 0.1486 %	17,442	0.1486 %	6 297 $
Renaissance Technologies LLC 0.1167 %	13,700	0.1167 %	4 946 $
Two Sigma Advisers LP 0.1082 %	12,700	0.1082 %	4 585 $
Two Sigma Investments LP 0.0887 %	10,417	0.0887 %	3 761 $
Warberg Asset Management LLC 0.0852 %	10,002	0.0852 %	3 611 $
Leonard Mazur 0.0422 %	4,949	0.0422 %	1 787 $
Tower Research Capital LLC 0.0128 %	1,503	0.0128 %	543 $
Wells Fargo Bank NA 0.000145 %	17	0.000145 %	6 $

Tharimmune, Inc.

1200 Route 22 East Suite 2000

08807, Bridgewater

http://www.hillstreambio.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.3905 USD

Average target price

5 USD

Spread / Average Target

+1,180.41%

Consensus

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
THARIMMUNE, INC.	-23.28%	4.6M
VERTEX PHARMACEUTICALS INCORPORATED	+8.63%	114B
REGENERON PHARMACEUTICALS, INC.	+13.17%	107B
BIONTECH SE	-12.76%	22.22B
ARGENX SE	-2.24%	21.28B
BEIGENE, LTD.	-7.19%	17.51B
WUXI APPTEC CO., LTD.	-39.93%	17.17B
NEUROCRINE BIOSCIENCES, INC.	+6.67%	14.14B
SAREPTA THERAPEUTICS, INC.	+33.90%	12.2B
LEGEND BIOTECH CORPORATION	-28.60%	7.83B

Bio Therapeutic Drugs